GPT and metabolic dysfunction-associated steatotic liver disease: However, other studies have suggested that ALT is not associated with liver histology in NAFLD [14] and because of this, the utility of ALT as a surrogate marker of response to treatment in early phase NAFLD clinical trials continues to be questioned.